This BNA’s Pharmaceutical Law & Industry Report article focuses on the major points of discussion for drug and biotech companies in 2016, including the reauthorization of drug user fee programs, drug pricing, and matters pertaining to biosimilars. Linda Bentley, a Member in the Mintz Boston office, is among the industry sources quoted in the piece.